Vor Biopharma, after significant restructuring, secured $175 million in private equity and in-licensed telitacicept from China’s RemeGen. This dual-action fusion protein targets BAFF and APRIL cytokines and is in Phase 3 for autoimmune diseases. The move marks Vor’s strategic shift from oncology to autoimmune disease drug development under new leadership with CEO Jean-Paul Kress, focusing on conditions like generalized myasthenia gravis.